This Week at FDA: New proposed rules, Biocon's Form 483, and more
Regulatory NewsMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsMichael MezherBiologics/ biosimilars/ vaccinesBiotechnologyMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy